PHARMACY

NCPA Foundation earns grant for student pharmacy program

BY Alaric DeArment

NEW ORLEANS The National Community Pharmacists Association Foundation has received a multi-year grant to expand a business plan contest for pharmacy students.

The association, which represents the country’s independent pharmacies and is having its 111th annual conference in New Orleans this week, announced Monday that the Good Neighbor Pharmacy had given it a $750,000 multiyear pledge to support the Pruitt-Schutte Student Business Plan Competition.

 

“We are excited to support NCPA’s efforts to recognize outstanding students of pharmacy,” said R. David Yost, president and CEO of Good Neighbor Pharmacy parent company AmerisourceBergen Corp. “We believe it is essential for pharmacy students to have access to high-quality business education, and this program helps provide that.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Sandoz launches two products

BY Alaric DeArment

PRINCETON, N.J. The generics arm of drug maker Novartis has launched two new products.

Sandoz announced the launch of topiramate sprinkle capsules, a generic version of Johnson & Johnson’s epilepsy drug Topamax Sprinkle, and calcium acetate capsules, an authorized generic of Fresenius Medical Care’s kidney failure drug PhosLo.

Topiramate capsules had sales of $56 million during the 12-month period ending in August, and PhosLo had sales of $42 million during the same period, according to IMS Health data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA approves GSK’s HPV vaccine

BY Alaric DeArment

PHILADELPHIA Merck & Co.’s highly successful human papillomavirus vaccine Gardasil has a new competitor.

The Food and Drug Administration approved GlaxoSmithKline’s Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant), for preventing infection by HPV – the virus that causes genital warts and can cause cervical cancer – in girls and women ages 10 to 25.

“The approval of Cervarix will bring an important new cervical cancer vaccine to girls and young women,” GSK president North American pharmaceuticals Deirdre Connelly said in a statement. “Immunization with a vaccine such as Cervarix – along with annual doctor visits and Pap tests – will help protect women from cervical cancer, the second leading cause of cancer death in women in their 20s and 30s.”

The FDA has already approved Merck’s Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for females and males ages 9 to 26.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?